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C E L L  B I O L O G Y
The orphan nuclear receptor LRH-1/NR5a2 critically 
regulates T cell functions
Carina Seitz1, Juan Huang1,2, Anna-Lena Geiselhöringer1, Pamela Galbani-Bianchi3, Svenja Michalek1, 
Truong San Phan1, Cindy Reinhold1, Lea Dietrich1, Christian Schmidt1, Nadia Corazza3, 
M. Eugenia Delgado1, Theresa Schnalzger1, Kristina Schoonjans4, Thomas Brunner1*
LRH-1 (liver receptor homolog-1/NR5a2) is an orphan nuclear receptor, which regulates glucose and lipid metabolism, 
as well as intestinal inflammation via the transcriptional control of intestinal glucocorticoid synthesis. Predominantly 
expressed in epithelial cells, its expression and role in immune cells are presently enigmatic. LRH-1 was found to 
be induced in immature and mature T lymphocytes upon stimulation. T cell–specific deletion of LRH-1 causes a 
drastic loss of mature peripheral T cells. LRH-1–depleted CD4+ T cells exert strongly reduced activation-induced 
proliferation in vitro and in vivo and fail to mount immune responses against model antigens and to induce experi-
mental intestinal inflammation. Similarly, LRH-1–deficient cytotoxic CD8+ T cells fail to control viral infections. 
This study describes a novel and critical role of LRH-1 in T cell maturation, functions, and immopathologies and 
proposes LRH-1 as an emerging pharmacological target in the treatment of T cell–mediated inflammatory diseases.
INTRODUCTION
An interaction between dietary and microbial-derived lipids and 
the immune system has been suggested for a long time. Food- and 
microbiome-derived lipids regulate host metabolism and thereby 
obesity, which, in turn, promotes inflammation and associated dis-
eases, such as type 2 diabetes and cancer [reviewed in (1) and (2)]. Best 
characterized is the role of short-chain fatty acids, such as butyrate 
and acetate, derived from bacterial digestion of food (3). However, 
also longer chain fatty acids and phospholipids are known to be taken 
up by the gastrointestinal tract and to regulate immunological 
processes [reviewed in (4)]. The underlying molecular mechanisms 
remain, so far, largely unexplored.
Lipid molecules are often bound and sensed by a large group of 
transcription factors, the nuclear receptor family. Nuclear receptors 
play important roles in various developmental, metabolic, and in-
flammatory processes. Lipid ligand binding promotes their tran-
scriptional activation via coactivator recruitment [reviewed in (5)]. 
Best characterized is the group of steroid hormone receptors, which 
bind cholesterol derivatives, such as sex hormones, aldosterone, 
and glucocorticoids. In particular, the glucocorticoid receptor is 
known to exert potent immunoregulatory activities, providing the 
basis for the efficient therapeutic use of synthetic glucocorticoids in 
the treatment of inflammatory processes (6). Endogenous glucocor-
ticoids are produced not only in the adrenal glands but also by extra- 
adrenal sources, such as the thymus, skin, lung, and intestine (7). 
Thus, we have previously shown that the intestinal epithelium is an 
important source of glucocorticoids and that intestinal glucocorti-
coids critically contribute to the regulation of local immune homeo-
stasis (8–11).
The synthesis of immunoregulatory glucocorticoids in the intes-
tinal epithelium is critically controlled by the nuclear receptor liver 
receptor homolog-1 (LRH-1/NR5a2) (9, 10), which belongs to the 
fushi tarazu family of transcription factors [reviewed in (12)]. Deletion 
of LRH-1 in the intestinal epithelium predisposes mice to development 
of intestinal inflammation due to the absence of local glucocorticoid 
synthesis (9). Furthermore, studies in patients with ulcerative colitis 
and Crohn’s disease revealed a clear negative correlation between 
LRH-1, intestinal glucocorticoids, and intestinal inflammation (9). 
LRH-1 is considered an orphan nuclear receptor, as no endogenous 
ligand has been identified so far. Various reports have, however, 
highlighted the fact that LRH-1 binds phospholipids, lipids, and 
lipophilic chemical compounds, resulting in transcriptional activation 
of the nuclear receptor (13, 14).
Although intestinal LRH-1 regulates immune cells via immunoreg-
ulatory glucocorticoids (10), little is currently known about the ex-
pression of LRH-1 in the hematopoietic system. Recently, a role of 
LRH-1 in the differentiation of macrophage subpopulations and the 
development of anti-infectious effector functions has been demon-
strated (15). Similarly, we were able to demonstrate that LRH-1 con-
tributes to the transcriptional control of Fas (CD95) ligand expression 
and associated effector functions in CD4+ T lymphocytes (16). How-
ever, the expression and role of LRH-1 in cells of the T cell lineage are 
currently unexplored and enigmatic. Here, we demonstrate a novel and 
direct role of LRH-1 in immune regulation. LRH-1 is expressed in 
murine thymocytes and mature T lymphocytes, and stimulation of cells 
further induces LRH-1 expression. CD4 promoter– driven deletion of 
LRH-1 at the CD4/CD8 double-positive stage in the thymus has only a 
minor impact on thymocyte maturation but severely reduces the 
number of peripheral T cells. While LRH-1–deficient T cells show 
normal signs of early T cell activation, they exert strongly reduced 
activation-induced proliferation in vitro and in vivo. LRH-1 deficiency 
severely impairs T cell responses and antibody production in vivo and 
abrogates CD4 T cell–mediated experimental colitis. Upon viral infec-
tion, LRH-1–deficient CD8+ T cells readily become activated and pro-
duce excessive amounts of cytokines yet fail to control virus expansion. 
This study demonstrates a critical role of LRH-1 in T cell maturation 
and the regulation of T cell homeostasis, T cell expansion, and effector 
functions. Furthermore, our study proposes LRH-1 as an emerging new 
target in the treatment of T cell–mediated inflammatory diseases.
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RESULTS
LRH-1 deletion results in reduced mature T cells
Because of the lack of information concerning the expression of 
LRH-1 in hematopoietic cells, we first investigated its gene expression 
profile in different lymphatic tissues (fig. S1A) and immature (fig. 
S1B) and mature T cell subsets (fig. S1C). This revealed that Nr5a2 
mRNA expression was low but detectable in all immature and mature 
T cell subsets of C57BL/6 wild-type mice (fig. S1, B and C) and in 
human peripheral blood mononuclear cells (PBMCs) (fig. S1D).
To address the role of LRH-1 in T lymphocytes, we next generated 
T cell–specific LRH-1–deficient mice using CD4 promoter–driven 
Cre recombinase expression [Nr5a2L2/L2 CD4-Cre, conditional knock-
out (cKO)]. As CD4 expression is first observed at the CD4+CD8+ 
stage of thymocyte maturation, we compared the thymi of cKO and 
control (L2/L2) animals but found no difference in size (fig. S2A), 
weight (fig. S2B), or cellularity (fig. S2C). Only a mild reduction of 
CD4+ and CD4+CD8+ and a corresponding increase in CD4−CD8− 
thymocytes were observed (fig. S2D).
When analyzing secondary lymphatic organs, we observed that the 
spleen of cKO animals was significantly reduced in size (Fig. 1A), organ 
weight (Fig. 1B), and cell numbers (Fig. 1C). Unexpectedly, CD8+ 
T cells were reduced by approximately 50%, and CD4+ lymphocytes were 
reduced by almost 80% in cKO spleens (Fig. 1D). In line with the signif-
icant loss of splenic CD3+ T cells (Fig. 1E), the relative number of B220+ 
B cells was increased (Fig. 1F) and no difference was observed for 
NK1.1+ (Fig. 1G) in cKO animals. The relative loss of CD4+ and CD8+ 
Fig. 1. Deletion of Nr5a2 leads to loss of mature T lymphocytes. (A) Representative picture of Nr5a2L2/L2 (L2/L2, ctrl) and Nr5a2L2/L2 CD4-Cre (cKO) spleens. ctrl, control. 
(B) Spleen organ weight relative to body weight (L2/L2, n = 17; cKO, n = 18 mice). (C) Spleen cellularity (n = 15). (D) Representative density plots of splenic CD4+ and CD8+ 
cells. The numbers indicate the percentage of cells. PE, phycoerythrin; FITC, fluorescein isothiocyanate. (E to G) Relative distribution of splenic CD3+ (E), B220+ (F), or NK1.1+ 
(G) CD3+ cells analyzed by flow cytometry (L2/L2, n = 11 mice; cKO, n = 12 mice per group). (H and I) Absolute numbers of splenic CD3+CD4+ and CD3+CD8+ T lymphocytes 
(L2/L2, n = 23; cKO, n = 17). (J) Representative hematoxylin and eosin (H&E) staining of L2/L2 or cKO spleens. (K) Representative immunohistology for CD3 (yellow) and 
B220 (blue) expression. (L) Representative staining for CD3 (yellow), F4/80 (red), and 4′,6-diamidino-2-phenylindole (DAPI) (blue). Scale bars, 0.5 cm (A) and 300 m (J to L). 
Mean values ± SD and individual values are shown in each graph. *P < 0.05 and ***P < 0.001. ns, not significant. Photo credit: Carina Seitz, University of Konstanz.
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T cells was confirmed when analyzing total cell numbers (Fig. 1, H and I). 
Comparable changes in CD4+ and CD8+ T cell numbers were found in 
axial (fig. S3, A to F) and mesenteric lymph nodes (fig. S3, G to L).
Because of the strong phenotype of LRH-1 deletion in mature 
T cell distribution, we next analyzed the splenic architecture. Histo-
logical analysis revealed obvious changes in the structure of white 
pulp follicles, which were more compact and with a lighter core, 
suggesting a reduced cell density (Fig. 1J). Immunohistological detec-
tion of B and T lymphocytes confirmed a reduced size of the T cell 
zone (Fig. 1K), while the overall distribution of B cell follicles and 
marginal zone macrophages (Fig. 1L) was not altered.
As CD4 promoter–driven deletion of LRH-1 had a stronger impact 
on numbers of peripheral CD4+ than CD8+ T cells, the question 
whether Cre-mediated deletion was less effective in CD8+ T cells 
arose. We thus used a Tomato-membrane green fluorescent protein 
(GFP) (mTmG) double-fluorescent Cre reporter mouse line, in 
which successful Cre-mediated recombination results in green 
fluorescence of cells (17). As expected, immature CD4−CD8− thy-
mocytes showed very low GFP levels and, hence, minimal LRH-1 
deletion (fig. S4A), while the deletion was nearly complete in more 
mature CD4+CD8+ thymocytes (fig. S4B), as well as in thymic, 
splenic, axial, and mesenteric CD4+ and CD8+ subsets (fig. S4, C, D, 
and F to H). Microscopic analysis of spleen sections confirmed specific 
LRH-1 deletion (GFP+) in the T cell area (fig. S4E). Overall, the rate 
of GFP+ CD8+ T cells was slightly lower, however, with 80 to 90% 
still almost complete.
Sensitivity of LRH-1–deficient T cells to apoptosis induction
To understand the underlying cause of LRH-1 deletion-mediated 
loss in peripheral T cells, we investigated the apoptosis sensitivity of 
cKO T cells. Enhanced basal cell death was observed in cKO thymo-
cytes (fig. S5, A to D) and splenocytes (fig. S6, A to D), while their 
response toward dexamethasone, etoposide, staurosporine, or plate- 
bound anti-CD3 promoting activation-induced cell death was com-
parable to the L2/L2 controls (figs. S5, A to D, and S6, A to D). 
Hence, increased stimulus-induced cell death does not appear to 
account for the selective loss of peripheral T cells in cKO mice.
As proliferating T cells are more sensitive to apoptosis-inducing 
agents, especially to activation-induced cell death (18), we addressed 
apoptosis induction in concanavalin A (ConA)–induced T cell blasts. 
Unexpectedly, cKO CD4+ cells and, to a lesser extent, CD8+ T cells 
failed to expand under these conditions and rather died, leading to 
approximately 80% basal cell death. This time-dependent increase 
in cell death of CD4+ cKO T cells was observed after ConA stimula-
tion (fig. S6E) and anti-CD3/anti-CD28 treatment (fig. S6F).
LRH-1–deficient T cells are not anergic
Because of the increased cell death in response to mitogenic stimuli, 
we tested the hypothesis that LRH-1–deficient T cells fail to become 
activated after T cell receptor stimulation. While the activation in-
duced up-regulation of the early activation markers CD69 and 
CD25 was slightly but significantly lower and slower in CD4+ and 
CD8+ cKO T cells, both responded to T cell activation by up-regulating 
both activation markers (Fig. 2, A and B).
To further exclude anergy as a cause of reduced numbers of 
LRH-1–deficient T cells, we analyzed their capability of effector 
cytokine expression and secretion. Interferon- (IFN-) secretion 
was detected in purified CD4+ and CD8+ T cells of both cKO 
and L2/L2 mice with even much higher levels in cKO T cells 
(Fig. 2C). Similar results were obtained for interleukin-2 (IL-2) 
Fig. 2. LRH-1–deficient T cells are not anergic. (A and B) Up-regulation of the early activation marker CD69 (A) and CD25 (B) in unstimulated (unstim) or anti-CD3 (3 g/ml) 
and anti-CD28 (1 g/ml) (stim) CD4+ or CD8+ splenic T cells (n = 3 mice). (C and D) Production of interferon- (IFN-) (C) or interleukin-2 (IL-2) (D) in purified CD4+ or CD8+ 
splenic T cells. Cells were stimulated as indicated for 48 hours, and cytokine secretion was determined by enzyme-linked immunosorbent assay (ELISA) (n = 4 mice). Mean 
values ± SD of triplicates or quadriplicates of representative experiments are shown. *P < 0.05, **P < 0.01, and ***P < 0.001.
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expression (Fig. 2D), confirming that LRH-1 deletion does not 
impair T cell activation.
Impaired activation-induced proliferation in  
LRH-1–deficient T cells
As cKO T cells were neither hypersensitive to stimulus-induced 
apoptosis induction nor anergic, we hypothesized that LRH-1 defi-
ciency directly affects T cell proliferation and expansion. Hence, we 
investigated the effect of mitogenic stimuli on Nr5a2 mRNA ex-
pression and found a significant increase in mouse splenocytes 
(Fig. 3A) and human PBMCs (Fig. 3B). Activation-induced Nr5a2 
expression closely correlated with cell cycle progression, as moni-
tored by the mRNA expression of cyclins (Fig. 3, C to E). As expected, 
expression of Myc, a direct regulator of the cell cycle machinery, 
was induced very early after activation (Fig. 3C). Nr5a2 expression 
was induced soon after stimulation with a peak at 3 to 6 hours 
(Fig. 3D), followed by cyclin E1 (Cdne1) (Fig. 3E), a transcriptional 
target of LRH-1 (19). We further observed increased LRH-1 pro-
moter activation in response to mitogenic stimulation in Jurkat lT cells 
(Fig. 3F), whereas serum withdrawal decreased LRH-1 promoter 
activity (Fig. 3G).
We next tracked spleen cell division by carboxyfluorescein diacetate 
succinimidyl ester (CFSE) dilution assay and observed a prominent 
reduction in LRH-1–deficient CD4+ T cells, while proliferation was 
not reduced or delayed in the CD8+ subset (Fig. 4, A and B). To 
confirm a role of LRH-1 in T cell proliferation, specific pharmaco-
logical inhibitors were applied to mimic the loss of LRH-1 protein. 
While the LRH-1 inhibitor 3d2 (20) resulted in significant inhibi-
tion of cell division even for the lowest concentrations, the inactive 
control substance cd7 (20) did not (Fig. 4, C and D). 3d2 was also 
able to inhibit CD8+ T cell proliferation, although higher concen-
trations were necessary (Fig. 4D). An inhibition of T cell proliferation 
was also observed with another LRH-1 inhibitor, SR1848 (Fig. 4E) 
(21). Reduced activation-induced proliferation of LRH-1–deficient 
T cells was confirmed by 3H-thymidine incorporation of highly purified 
CD4+ and CD8+ T cells (Fig. 4F), suggesting that also in the absence 
of splenic accessory cells, CD8+ T cells depend on LRH-1. To under-
stand the molecular basis of this reduced proliferation, we analyzed the 
expression of cell cycle–regulating target genes of LRH-1, i.e., c-Myc 
(Myc) and cyclin E1 (Cdne1) (19, 22). In agreement with the reduced 
proliferation observed in activated cKO T cells, a reduced induction 
Myc and Cdne1 expression was seen in CD4+ cKO T cells and re-
duced Myc expression in CD8+ T cells (Fig. 4, G and H).
We next assessed the role of LRH-1 in homeostatic T cell expan-
sion in vivo by adoptively transferring purified cKO or L2/L2 T cells 
into lymphopenic recipient mice. Analysis of spleen and mesenteric 
lymph nodes revealed major defects of CD4+ cKO T cell expansion 
and reduced repopulation of LRH-1–deficient CD8+ T cells (fig. S7, 
A and B). To further monitor activation-induced T cell expansion 
in vivo, we analyzed the ex vivo T cell restimulation of ovalbumin- 
immunized mice. While an antigen-dependent proliferation of 
T cells was detectable in immunized L2/L2 mice, no ex vivo prolifer-
ation was seen in T cells from cKO mice (fig. S8, A and B). In addi-
tion to the lack of ovalbumin-induced T cell expansion in vivo, a 
massive reduction of anti-ovalbumin immunoglobulins in the sera 
of cKO mice was observed, revealing defects in T cell–dependent 
B cell activation (fig. S8C).
Impaired colitis induction by LRH-1–deficient T cells
To test the consequence of impaired proliferation in a T cell–dependent 
pathogenesis model in vivo, we used the T cell transfer colitis model. 
In this model, naïve CD4+ CD45Rbhi T cells are transferred into 
Fig. 3. Nr5a2 expression is up-regulated upon stimulation.  (A) Nr5a2 mRNA expression in wild-type spleenocytes after 3 hours of phorbol myristate acetate (PMA) and 
ionomycin (iono) or ConA stimulation, normalized to unstimulated control (n = 3 mice per group). (B) NR5A2 mRNA expression in human PBMCs (hPBMCs) after stimu-
lation with phytohemagglutinin (PHA-P) for 3 hours (n = 3 biological replicates). (C to E) Kinetics of (C) Myc, (D) Nr5a2, and (E) Cdne1 expression in splenocytes after 
anti-CD3/anti-CD28 stimulation normalized to unstimulated control (n = 3 mice). (F) Induction of NR5A2 promoter activity in Jurkat lT cells after stimulation with PMA and 
ionomycin. One representative experiment of five is shown (n = 3 technical replicates). (G) Effect of serum deprivation on NR5A2 promoter activity. One of three rep-
resentative experiments is shown (n = 3 technical replicates). *P < 0.05, **P < 0.01, and ***P < 0.001.
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lymphopenic Rag1−/− mice, where their uncontrolled activation by 
gut microbiota leads to subsequent colitis induction (Fig. 5A) (23, 24). 
While transfer of L2/L2 T cells resulted in a time-dependent loss of 
body weight (Fig. 5B) and massive colonic inflammation, cKO T cell 
transfer failed to promote body weight loss and caused significantly 
less colonic inflammation (Fig. 5, C to E). The reduced colitis in-
duction of cKO donor cells observed was paralleled by diminished 
T cell expansion and repopulation of spleen and mesenteric lymph 
Fig. 4. Impaired cell proliferation in LRH-1–deficient T cells. (A and B) Cell proliferation in response to anti-CD3 ± anti-CD28 stimulation of splenic CD4+ and CD8+ 
T cells was analyzed by CFSE dilution after 72 hours. Mean values ± SD of three individual experiments are shown. (C and D) Spleen cells were stimulated with anti-CD3 
and anti-CD28 in the presence or absence of the LRH-1 antagonist 3d2 or control substance cd7 at indicated concentrations, and proliferation was analyzed by CFSE di-
lution at 72 hours. Values were normalized to stimulated cells without inhibitors (n = 3 mice). (E) Splenocytes were treated with or without the LRH-1 inhibitor SR1848 and 
stimulated with anti-CD3/anti-CD28; cell proliferation was analyzed by CFSE dilution at 72 hours (n = 3 mice). (F) Activation-induced 3H-thymidine incorporation in puri-
fied CD4+ and CD8+ splenic T cells after 72 hours, normalized to unstimulated cells. Mean values ± SD of a representative experiment are shown (n = 5 experiments). 
(G and H) Activation-induced Myc (G) and Cdne1 (H) mRNA expression in purified CD4+ and CD8+ splenic T cells after 24 hours. *P < 0.05, **P < 0.01, and ***P < 0.001.
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node (Fig. 5, F and G) and reduced IFN- expression in the colon of 
Rag1-deficient recipient mice (Fig. 5. H to J).
Reduced regulatory function of LRH-1–deficient T cells
To further study the putative role of LRH-1 in regulatory T cells 
(Tregs), we conducted a colitis protection experiment. While naïve 
CD4+ CD45Rbhi T cells are able to infiltrate colonic tissue and 
induce colitis upon transfer into lymphopenic mice, cotransfer of 
CD4+ CD45Rblo T cells results in pronounced protection from coli-
tis induction, mediated by Tregs in this T cell population (fig. S9A) 
(24, 25). Accordingly, the transfer of Ly5.1+ CD4+ CD45Rbhi T cells 
caused pronounced colitis, accompanied by body weight loss (fig. 
S9B) and colonic inflammation (fig. S9C), whereas the cotransfer of 
CD4+ CD45Rblo T cells from L2/L2 mice resulted in the restoration 
of body weight loss (fig. S9B) and reduced colonic inflammation 
(fig. S9D). In marked contrast, sort-purified cKO CD4+ CD45Rblo 
T cells were unable to attenuate disease development (fig. S9, B and 
E). Along these lines, reduced regulatory cKO donor T cell numbers 
were found in spleen (fig. S9F) and mesenteric lymph nodes (fig. S9G) 
of recipient mice, suggesting that the disturbed protective functions of 
cKO T cells resulted from reduced in vivo expansion. While L2/L2 Tregs 
were able to significantly reduce colonic Ifng mRNA expression and 
cKO T cells failed to do so (fig. S9H), there was no difference in Il1b 
expression (fig. S9I), but Treg populations from both L2/L2 and cKO 
mice promoted a significant reduction of colitis-induced Tnfa mRNA 
expression (fig. S9J). To exclude that the lack of protection by CD4+ 
CD45Rblo cKO T cells was caused by a reduced frequency of Treg in 
this population, we determined the percentage of splenic FoxP3+ 
CD4+ T cells in L2/L2 and cKO mice before transfer, revealing no 
difference (fig. S9K).
Impaired virus clearance by LRH-1–deficient cytotoxic T cells
The impact of LRH-1 deletion was more pronounced in regard to 
mature CD4+ T cell numbers, while CD8+ T lymphocytes were less 
affected. To investigate the effect of LRH-1 deletion on CD8+ T cell 
effector functions, we analyzed the antigen-specific T cell expansion 
and viral clearance after lymphocytic choriomeningitis virus (LCMV) 
infection, which is critically dependent on cytotoxic CD8+ T cells 
(26). Accordingly, LCMV infection resulted in increased numbers 
of splenic CD8+  T cell receptor–positive (TCR+) cells in L2/
L2 mice at day 6 after LCMV infection, indicative of a virus-specific T cell 
expansion. Although cKO mice had lower numbers of CD8+ TCR+ 
Fig. 5. Impaired colitis induction by LRH-1–deficient CD4+T cells. (A) Scheme of transfer colitis induction in Rag1−/− recipient mice. (B) Colitis-induced loss of body 
weight (L2/L2 donor, n = 14; cKO donor, n = 9). (C to E) Representative histologies of colon samples from untreated Rag1−/− recipient mice (C) or after transfer of naïve L2/L2 
(D) or cKO T cells (E). Top panels: Lower magnification. Bottom panels: Higher magnification. Scale bars, 150 m. (F and G) Repopulation of spleen (F) or mesenteric lymph 
node (mLN) (G) by naïve L2/L2 or cKO T cells. (H to J) mRNA expression levels of the proinflammatory cytokines tumor necrosis factor– (H), IL-1 (I), and IFN- (J) in colon 
samples or control recipients or recipients transferred with L2/L2 or cKO T cells. Mean ± SD and individual data points of n = 9 to 14 mice are shown. *P < 0.05, **P < 0.01, 
and ***P < 0.001.
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cells before infection, a clear virus-induced expansion was observed 
at days 6 and 8 after infection (Fig. 6A). Along with the virus-induced 
cytotoxic T cell expansion, an increase in CD69+ and CD25+ CD8+ 
T cells was observed at day 6 after infection; however, no difference 
was seen between L2/L2 and cKO mice (Fig. 6, B and C). Similarly, 
a comparable virus-induced increase of CD25+ CD8+ T cells in mes-
enteric lymph nodes was observed (fig. S10A). The expansion of 
virus-specific T cells was confirmed using intracellular staining of 
IFN-. While only ex vivo restimulation with the LCMV peptide 
gp33, but not the control peptide adn5, resulted in IFN-+ CD8+ 
T cells at days 6 and 8 after infection, no difference was seen be-
tween control and cKO mice (Fig. 6D). Similar observations were 
made when analyzing IFN- levels in serum samples (fig. S10B). 
Thus, LRH-1 deficiency does not appear to affect LCMV-induced 
CD8+ T cell activation and expansion.
An important effector function of virus-specific T cells is the 
killing of virus-infected cells and, thereby, virus clearance. Accord-
ingly, a massive reduction of virus particles was seen in the spleen, 
liver, small intestine, and serum of LCMV-infected control mice at 
day 10 after infection (Fig. 6, E to H). However, while CD8+ cKO 
T cells appeared to become properly activated and expand after 
LCMV infection, they completely failed to control viral expansion, 
Fig. 6. Impaired virus clearance by LRH-1–deficient cytotoxic T cells. (A) Virus-induced expansion of CD8+ TCR+ T cells [0 days post infection (dpi), n = 11; 6 dpi, 
n = 9; 8 dpi, n = 3 mice]. (B and C) Up-regulation of activation marker CD69 (B) and CD25 (C) in CD8+ T cells after LCMV infection (0 dpi, n = 11; 6 dpi, n = 9; 8 dpi, n = 6 mice). 
(D) Quantification of IFN-–producing virus-specific CD8+ T cells after ex vivo restimulation with buffer control, Adn5 control peptide or GP33 peptide (0 dpi: n = 8; 6 dpi: 
n = 9; 8 dpi: n = 6 mice). (E to H) Virus titers after LCMV infection of L2/L2 or cKO mice in the spleen (E), liver (F), small intestine (G), and serum (H) (6 dpi, n = 9; 8 dpi, n = 6; 
10 dpi, n = 7 mice). (I) Immunohistological detection of LCMV-infected cells in liver sections in L2/L2 or cKO mice at days 6 and day 10 after infection. VL4 LCMV nucleo-
protein, red; nuclei, blue (DAPI). Representative pictures are shown. Scale bars, 150 m. (J) mRNA expression of the cytotoxic T cell effector molecule perforin (Prf1) (0 dpi, 
n = 5; 6 dpi, n = 5; 8 dpi, n = 6; 10 dpi, n = 2 mice). (K) DNA fragmentation of GP33 or Adn5-loaded EL4 cells by virus-specific T cells, 8 days after LCMV infection, measured 
by loss of 3H-thymidine (n = 3 mice; representative experiment of two is shown). *P < 0.05, **P < 0.01, ***P < 0.001. E:T, effector:target.
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resulting in a high viral load in all tissues examined (Fig. 6, E to H). 
The lack of viral clearance was also obvious when detecting LCMV- 
infected cells in liver tissue using immunofluorescence. While con-
trol mice almost completely cleared the virus from liver tissue at day 10 
after infection, cKO mice still contained high numbers of virus- 
producing hepatocytes (Fig. 6I). As LCMV clearance is critically 
dependent on perforin-mediated cytotoxicity (27), we analyzed Prf1 
and Gzmb mRNA expression in the spleen of control and cKO 
mice, revealing an infection-induced increase in both mouse lines 
(Fig. 6J and fig. S10C). Furthermore, spleen cells and sorted CD8+ 
T cells from both virus-infected control and cKO mice killed LCMV 
peptide–presenting target cells equally well (Fig. 6K and fig. S10D). 
This indicates that impaired expression of cytotoxic effector mole-
cules is not responsible for the inability of cKO T cells to clear LCMV.
DISCUSSION
The expression and role of LRH-1 has been well described in vari-
ous endodermal tissues, while considerably less is known about its 
expression and role in other tissues, specifically the hematopoietic 
system. The first indirect report investigating the LRH-1 expression 
in pancreatic tumors, where they accidentally observed LRH-1–
positive tumor-infiltrating leukocytes, came from Benod and col-
leagues (28). More recently, Lefèvre et al. (15) described LRH-1 
expression in macrophages and a role of LRH-1 in cytokine-induced 
differentiation. Our own studies revealed a role of LRH-1 in the 
transcriptional control of Fas ligand expression in CD4+ T cells 
(16). However, besides these few studies, the expression and role of 
LRH-1 in the hematopoietic system is currently unexplored. One of 
the underlying reasons seems to be that steady-state levels are ex-
tremely low; thus, LRH-1 expression and function in immune cells 
had been largely ignored. We observed that expression levels in un-
stimulated thymocytes and mature T cells are about 100 to 1000 
times lower than those observed in the intestine and the liver (fig. S1, 
A to D). However, LRH-1 expression in T cells appears to be rather 
dynamic. Activation of T cells by mitogenic stimuli strongly induces 
LRH-1 promoter activity, expression, and function (Fig. 3, A, B, D, 
and F). LRH-1 induction by mitogenic stimuli correlates well with 
the up-regulation of cell cycle–regulating genes, i.e., c-Myc and cy-
clin E1 (Fig. 3, C to E). This is in line with the established role of 
LRH-1 in the transcriptional control of these cyclin genes and the 
regulation of proliferation of intestinal epithelial stem cells and tu-
mor cells (19). Supporting a suggested role of LRH-1 in cell cycle 
progression, we observed a profound inhibition of activation-induced 
proliferation when LRH-1 was either genetically deleted or pharma-
cologically inhibited (Fig. 4, A to F). Reduced proliferation was observed 
not only in vitro but also during homeostatic expansion in vivo (fig. S7, 
A and B) and the pathogenesis of experimental colitis (Fig. 5, A to G). 
This proliferation deficiency is unlikely a consequence of improper 
T cell activation, as LRH-1–deficient T cells readily up-regulated 
early activation markers (Fig. 2, A and B), and levels of IL-2 and 
IFN- produced often exceeded those of control T cells (Fig. 2, C 
and D). Given the previously described role of LRH-1 in the tran-
scriptional regulation of cell cycle–related genes, e.g., cyclin D1 and 
E1 and c-Myc, in the liver and intestinal epithelial cells (19), the lack 
of LRH-1 very likely leads to defects in activation-induced prolifer-
ation in T cells due to reduced expression of these LRH-1 target 
genes. We have seen that cyclin E1 (Cdne1) and c-Myc (Myc) are ex-
pressed at reduced levels in LRH-1–deficient T cells (Fig. 4, G and H).
Unexpectedly, we observed quite substantial differences between 
the impact of LRH-1 deletion on CD4+ versus CD8+ T cells (Fig. 1, 
D, H, and I). While LRH-1 deletion resulted in a threefold reduction 
of mature peripheral CD4+ T cells, CD8+ T cells were only reduced 
by half (Fig 1, H and I). Similarly, activation-induced proliferation 
of CD8+ T cells appeared to be less dependent on LRH-1, as in a 
mixed spleen cell population CD8+ T cells divided normally in re-
sponse to TCR stimulation, while CD4+ were severely impaired (Fig. 4, 
A and B). During homeostatic T cell expansion in vivo, LRH-1– 
deficient CD8+ T cells barely differed from wild-type T cells, while 
LRH-1–deficient CD4+ T cells were not able to compete with wild-
type T cells in repopulating Rag1−/− recipients (fig. S7, A and B). In 
addition, during LCMV infection, a normal expansion of LRH-1–
deficient virus-specific CD8+ T cells was observed, although they 
started at a lower level (Fig. 6A). As the CD4 promoter becomes 
activated already at the double-positive stage during thymic matu-
ration, the LRH-1 gene is already deleted at this stage of T cell devel-
opment (fig. S4, A to D). As CD4 promoter activity drops in mature 
CD8+ T cells, an insufficient duration of Cre expression and associated 
failure to completely delete the LRH-1 gene could account for the 
reduced impact of LRH-1 deletion in CD8+ T cells. However, the 
use of the mTmG double-fluorescent reporter mouse revealed effi-
cient Cre-mediated conversion of tdTomato-positive to GFP-positive 
cells in both CD4+ and CD8+ T cell populations, although Cre- 
mediated excision appeared to be slightly more efficient in CD4+ T cells 
(fig. S4, F to H). Nonetheless, it is unlikely that incomplete LRH-1 
deletion accounts for the differences in proliferation observed, as 
the vast majority of LRH-1–deficient CD8+ T cells were also GFP+, 
indicating a sufficient phase of active Cre recombinase during their 
development. The difference in LRH-1 dependency between CD4+ 
and CD8+ T cells may be rather related to the presence or absence of 
compensatory signals. LRH-1–deficient CD8+ T cells showed pro-
liferation defects only when highly purified (Fig. 4F) but not when 
stimulated in the presence of antigen-presenting cells (Fig. 4, B and D). 
Thus, costimulatory signals distinct from B7-CD28 interaction 
may provide compensatory signals, enabling LRH-1–independent 
proliferation.
Defects in CD4+ T cell proliferation correlated well with the in-
ability of LRH-1–deficient CD45RBhi CD4+ T cells to promote in-
flammation in the transfer model of colitis (Fig. 5, A to H). Similarly, 
the LRH-1–deficient Tregs in the CD45RBlo CD4+ T cell population 
also failed to expand in vivo and to mediate protection from colitis 
induction (fig. S9, A to G). This inability to prevent transfer colitis 
is not due to a generally reduced level of Tregs, as the percentage of 
FoxP3+ Tregs among splenic CD4+ T cells was similar in control and 
LRH-1–deficient mice (fig. S9K). Thus, this rather suggests that 
in vivo proliferation of CD4+ Tregs is also critically controlled by 
LRH-1. A somewhat different situation was observed in the LCMV 
infection model. Although T cell–specific LRH-1–deficient mice 
had generally lower numbers of CD8+ T cells before infection, 
LCMV promoted a rapid expansion of virus-specific T cells even in 
the absence of LRH-1, as seen by a general increase in CD8+ TCR+ 
T cells in the spleen (Fig. 6A) and lymph nodes (fig. S10A) and 
comparable numbers of IFN-–producing CD8+ T cells upon ex vivo 
restimulation with the LCMV-specific peptide gp33 (Fig. 6D). Also 
along these lines, comparable production of cytokines and an in-
crease in activation marker–positive (CD25 and CD69) CD8+ 
T cells were observed (Fig. 6, B and C, and fig. S10B). In marked 
contrast, LRH-1–deficient cytotoxic T cells failed to control viral 
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spreading. While in control animals LCMV titers were reduced at 
day 10 after infection by several logs and barely detectable, viral 
titers in mice with defective LRH-1 expression remained at a high 
level (Fig. 6, E to I). Given that virus-specific T cells appeared to 
expand normally, this difference is difficult to reconcile. An obvious 
guess would be that LRH-1–deficient CD8+ T cells fail to express 
cytotoxic effector molecules. However, gene expression analysis re-
vealed that granzyme B and perforin are, at least on an mRNA level, 
induced upon viral infection and equally expressed in control and 
cKO mice (Fig. 6J and fig. S10C). While we have recently identified 
the cytotoxic effector molecule Fas ligand as a target gene of LRH-1 
(16), it is unlikely that impaired Fas ligand expression could account 
for inefficient viral clearance, as perforin (27) but not Fas ligand 
(29) is critical for controlling LCMV spreading. Furthermore, we 
confirmed that T cells from both virus-infected control and cKO 
mice killed LCMV peptide–presenting target cells equally well, sug-
gesting normal cytotoxic effector functions in both mouse lines.
Thus, alternative mechanisms have to be considered for the inef-
ficiency of cKO mice to control LCMV. A possible explanation is 
that CD8+ cells expand but cannot reach critical numbers to effi-
ciently eliminate LCMV. Another possibility is that cKO T cells are 
more readily exhausted and thereby cannot control viral expansion. 
Alternatively, an efficient cytotoxic T cell response may also depend 
on proper T helper cell responses, which is likely impaired in cKO 
mice with reduced proliferative potential of CD4+ T cells. In sup-
port of this hypothesis, it was reported that CD4+ T cell help was 
required for effective CD8+ T cell–mediated resolution of LCMV 
infection (30). Thus, T helper cells have been shown to critically 
orchestrate expansion and recruitment of cytotoxic CD8+ T cells 
[reviewed in (31)].
An interesting aspect of our study is its potential translational 
application. Although no endogenous ligands for LRH-1 have been 
identified yet, a number of pharmacological inhibitors with high 
specificity have been developed. The fact that transient inhibition of 
LRH-1 with two inhibitors that act in different mechanisms [3d2 
(Fig. 4, C and D) (20) and SR1848 (Fig. 4, E and F) (21)] was able to 
confirm that the proliferation-regulating role of LRH-1 in T cells 
and the relatively low expression of LRH-1 in comparison to the 
liver and intestine may open an interesting therapeutic window. 
The use of LRH-1 inhibitors in relatively low doses could permit the 
efficient inhibition of T cell mediated immunopathologies while 
not affecting vital functions of other tissues. While studying the role 
of LRH-1 in the transcriptional control of Fas ligand, we were al-
ready able to provide proof of principle for this concept. Injection of 
the lectin ConA into mice leads to rapid T cell activation and Fas 
ligand–dependent damage of the liver, which was strongly reduced 
after administration of 3d2 (16). The liver seems to tolerate 3d2 rel-
atively well, as only a minimal increase in 3d2-induced serum trans-
aminases was observed.
In summary, we have described a novel role for LRH-1 in T cell 
development, proliferation, and effector functions. Furthermore, 
our study proposes LRH-1 as an emerging new target in the treat-
ment of T cell–mediated inflammatory diseases.
MATERIALS AND METHODS
Mice
Animals were housed in individually ventilated cages at the central 
animal facility of the University of Konstanz. Male and female mice 
aged 7 to 15 weeks on C57BL/6 background carrying the leukocyte 
marker CD45.2 were used for all in vitro and in vivo experiments 
unless otherwise stated. For mRNA quantitation experiments, wild-
type C57BL/6 mice were used. Nr5a2L2/L2 (L2/L2) mice (9) were 
bred with CD4-Cre transgenic mice (32) to obtain Nr5a2L2/L2 CD4-
Cre (cKO) animals and kept heterozygous for Cre expression. The 
Cre-reporter mTmG transgenic mice were provided by U. Koch 
(École Polytechnique Fédérale de Lausanne) and crossed with Nr5a2L2/L2 
CD4-Cre to obtain Nr5a2L2/L2 mTmG CD4-Cre mice. Throughout 
all experiments, cKO animals were compared to their correspond-
ing floxed littermate controls. Ly5.1 mice expressed the leukocyte 
marker CD45 isoform 1. Rag1−/− (provided by M. Basler, University 
of Konstanz) mice were bred on a Ly5.1 background.
Cell culture and reagents
All experiments were performed in 96-well round-bottom plates 
(Greiner) in technical triplicates with 200,000 cells per well in com-
plete culture medium unless otherwise stated. Cell culture media 
and supplements were purchased from Sigma-Aldrich, if not other-
wise indicated.
Human leukemic Jurkat cells (the American Type Culture Collection) 
with stably transfected SV40 large T antigen (lT) were maintained 
in RPMI 1640 medium supplemented with 5% fetal calf serum 
(FCS), 2 mM l-glutamine, and gentamycin (20 g/ml) at 37°C and 
5% CO2. Cells have been routinely tested for the absence of myco-
plasma. Mouse T cells were cultured in RPMI 1640 medium supple-
mented with 10% FCS, 2 mM l-glutamine, gentamycin (20 g/ml ), 
and 50 M -mercaptoethanol.
Luciferase reporter assay
The 1.5-kb human LRH-1 promoter luciferase reporter and control 
constructs have been described previously (33). Jurkat lT cells were 
transfected by nucleofection (Amaxa) (16), seeded at a concentra-
tion of 3 × 105 cells/ml in 12-well plates, and cultured overnight 
before treatment with phorbol myristate acetate (PMA) (50 ng/ml) 
and ionomycin (1.1 g/ml ) (both from Enzo Life Sciences) or se-
rum withdrawal for further 24 hours. Luciferase assays were carried 
out as described previously (34). Chemiluminescence was mea-
sured using an Infinite 200 PRO (Tecan) microplate reader. 
pCMV -galactosidase was used to correct for transfection effi-
ciencies. To test endogenous LRH-1 activity, Jurkat lT cells were 
transfected with a luciferase reporter construct containing 5× 
LRH-1 response elements derived from the small heterodimer 
partner promoter (35).
T cell isolation and activation
Single-cell suspensions from the spleen, thymus, and lymph 
nodes were prepared by manual disruption between frosted 
glass slides. Human PBMCs were prepared by Ficoll density 
centrifugation.
For Nr5a2 mRNA quantitation experiments, freshly isolated 
splenocytes were stimulated with 5 g/ml ConA (Sigma-Aldrich) or 
PMA (5 ng/ml) and ionomycin (200 ng/ml) for 3 hours and imme-
diately frozen in appropriate reagents for subsequent mRNA analysis. 
Alternatively, cells were activated with anti-CD3 antibody (3 g/ml) 
(clone 145-2C11) and precoated on 96-well flat bottom plates in 
50 mM tris (pH 9) and soluble purified anti-CD28 antibody (1 g/ml) 
(BioLegend). ConA-activated mouse splenocytes were prepared as 
a source of T cell blasts and cultured as described (16). Human PBMC 
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were treated with phytohemagglutinin (5 g/ml) (Sigma-Aldrich) 
for 3 hours before RNA isolation.
RNA isolation and real time quantitative polymerase  
chain reaction
Tissue RNA was isolated using peqGOLD TriFast (Peqlab) accord-
ing to the manufacturer’s instructions. For sorted cells, the ReliaPrep 
RNA Mini Kit (Promega) was used. Complementary DNA (cDNA) 
was prepared using the High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems). Quantitative polymerase chain reac-
tion (PCR) was performed on a StepOnePlus Instrument using SYBR 
Green PCR Master Mix (both from Applied Biosystems). Primers 
were designed to span exon-exon junctions. Gene expression was 
normalized to Actb or GAPDH, respectively. The following primers 
were used: Nr5a2, 5′-TTGAGTGGGCCAGGAGTAGT-3′ (forward) 
and 5′-ACGCGACTTCTGTGTGTGAG-3′ (reverse); Actb, 5′-TATTG-
GCAACGAGCG GTTCC-3′ (forward) and 5′-GCACTGTGTTGG-
CATAGAGG-3′ (reverse); Myc, 5′-CTAGTGCTGCATGAGGAGAC-3′ 
(forward) and 5′-TTTGCCTCTTCTCCACAGAC-3′ (reverse); Cdne1, 
5′-TTCTGCAGCGTCATCCTCTC-3′ (forward) and 5′-TGTGC-
CAAGTAGAACGTCTC-3′ (reverse); Tnfa, 5′-TAGCCCACGTC-
GTAGCAAAC-3′ (forward) and 5′-ACAAGGTACAACCCATCGGC-3′ 
(reverse); Il1b, 5′-TGCCACCTTTTGACAGTGATG-3′ (forward) 
and 5′-ATGTGCTGCTGCGAGATTTG-3′ (reverse); Ifng , 
5′-CGGCACAGTCATTGAAAGCC-3′ (forward) and 5′-TGT-
CACCATCCTTTTGCCAGT-3′ (reverse); Prf1, 5′-TCTTGGTGG-
GACTTCAGCTTT-3′ (forward) and 5′-TCCATACACCTGG-
CACGAAC-3′ (reverse); Gzmb, 5′-GCTGCTAAAGCTGAAGAGTAAGG-3′ 
(forward) and 5′-TCACATTGACATTGCGCCTG-3′ (reverse); human 
NR5A2, 5′-GGGCAACAAGTGGACTATTC-3′ (forward) and 5′-CCAGCT-
GGAAGTTTTCAAGG-3′ (reverse); and human GAPDH, 5′-ATG-
GAGAAGGCTGGGGCTCA-3′ (forward) and 5′-AGTGATGGCAT-
GGACTGTGGTCAT-3′ (reverse).
Flow cytometry and cell sorting
Single-cell suspensions of freshly isolated T cells were stained with 
one or more of the following monoclonal antibodies: anti–CD3-APC 
(anaphase-promoting complex) (145-2C11), anti–CD8-PE (phyco-
erythrin) (53-6.7), anti–CD45.1-BV421 (A20), anti–CDCD45.2-APC 
(104), anti–CD4-FITC (fluorescein isothiocyanate) (RM4-5), and 
anti–CD8–PerCP-Cy5.5 (53-6.7) from BD Pharmingen; anti–CD4-Cy5 
(GK1.5), anti–CD25-APC (PC61.5), anti–F4/80-APC (BM8), anti–
NK1.1-PE (PK136), anti–CD45R (B220)–PerCP-Cy5.5 (RA3-6B2), 
anti–CD4-PE (GK1.5), anti–CD8-FITC (eBioH35-17.2), anti–FoxP3-PE 
(FJK-16s), and anti–TCR-PE-Cy7 (H57-597) from eBioscience; 
anti–IFN-–FITC (XMG1.2) and anti–CD69-PE (H1.2F3) from 
BioLegend; and anti–CD3-FITC (145-2C11; purified from culture 
supernatant); anti-VL4 antibody was a gift from M. Basler (University of 
Konstanz). The following polyclonal secondary antibodies were used: 
goat anti-rat immunoglobulin G (IgG)–Alexa Fluor 568 (Invitrogen) 
and goat anti-hamster IgG-FITC cocktail (G70-204/G94-56, BD 
Pharmingen). Flow cytometry was performed on an LSRFortessa 
(BD Biosciences). For cell sorting, an Aria III (BD Biosciences) 
instrument was used. Data were analyzed using FlowJo software 
(TreeStar).
For intracellular cytokine staining, cells were restimulated 
in vitro with gp33 peptide (1 g/ml) (KAVYNFATC) or adn5 con-
trol peptide (SGPSNTPPEI; both from ProImmune) and incubated with 
brefeldin A (10 g/ml) (LKT Labs) for 5 hours. Staining (anti–CD8-PE 
and anti–IFN-–FITC) was performed as described before (36). For de-
tection of Tregs, splenocytes were surface-stained with anti–CD4-FITC 
before they were stained intracellularly with anti–FoxP3-PE using the 
Fix/Perm Kit (BioLegend).
Histology and immunohistochemistry
Mouse colons and small intestinal segments were swiss-rolled and 
fixed in 10% formalin, followed by paraffin embedding. Tissue sec-
tions (4 m) were stained with hematoxylin and eosin for histological 
analysis using standard procedures.
For immunohistochemistry, organs were immediately embed-
ded in O.C.T. (Tissue-Tek) cryosection medium and shock frozen 
on dry ice. Sections (7 m) were cut, and samples were fixed with 
fresh acetone for 1 min, treated with anti-CD16/32 Fc-block, stained 
with appropriate antibodies, and detected with Alexa Fluor 568– 
and FITC-conjugated secondary antibodies. mTmG cryosections 
were directly analyzed without further processing. All sections were 
embedded in 4′,6-diamidino-2-phenylindole containing Fluoroshield 
(Sigma-Aldrich) and analyzed on an Axio Observer Z1 (Zeiss) mi-
croscope. Fiji software (37) was used for image processing.
Cell death assays
Isolated T cells were cultured in the presence or absence of dexa-
methasone (Sigma-Aldrich), etoposide (Enzo Life Sciences), stau-
rosporine (Sigma-Aldrich), plate bound anti-CD3 antibody, or solvent 
control (dimethyl sulfoxide or ethanol) for 8 hours. Cells were counter-
stained with anti–CD4-Cy5 and anti–CD8-PE in binding buffer 
and analyzed for annexin-V positivity, as described (38).
Proliferation assays
Lymphocyte proliferation was monitored using CFSE (Sigma-Aldrich) 
dilution, as described (39). Cells were counterstained with anti–CD4-Cy5 
and anti–CD8-PE and analyzed by flow cytometry. In some experi-
ments, the pharmacological LRH-1 inhibitor 3d2 (20), control sub-
stance cd7 (20) (both synthesized by ChemBridge Corporation), or 
SR1848 (21) were added 30 min before T cell activation.
For 3H-thymidine incorporation assays, cells were pulsed with 
0.5 Ci 3H-thymidine (Hartmann Analytic) per well for 18 hours 
and harvested using a semiautomated cell harvester (Packard). 
3H-thymidine integration was determined by scintillation counting. 
For cell cycle profile analysis, wild-type splenocytes were cultured 
for indicated time points before nuclear DNA content was analyzed 
as described earlier (40).
Analysis of cytokine expression and serum  
immunoglobulin titers
Secretion of murine IL-2 and IFN- was quantified by enzyme-linked 
immunosorbent assay (ELISA) using matched antibody pairs [anti- 
mouse IFN- (RA-6A2/XMG1.2) and anti-mouse IL-2 (JES6-1A12/
JES6-5H4)]. All reagents were purchased from BioLegend and used 
according to the manufacturer’s instructions.
For the determination of anti-ovalbumin–specific IgG antibodies 
in mouse serum, polystyrene microtiter plates (Nunc) were coated 
with ovalbumin (100 g/ml) and horseradish-conjugated goat anti- 
mouse IgG (Jackson ImmunoResearch) was used for detection.
Ovalbumin immunization and in vitro restimulation
Mice were subcutaneously injected with 100 g of ovalbumin emul-
sified in incomplete Freund’s adjuvant (Invivogen). After 14 days, 
Seitz et al., Sci. Adv. 2019; 5 : eaav9732     17 July 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 12
the spleen and serum were isolated for further analysis of antibody 
production by ELISA and proliferation of antigen-specific T cells by 
in vitro restimulation and 3H-thymidine incorporation.
Adoptive transfer studies
Isolated splenocytes were sorted accordingly on the basis of CD4 
and CD8 staining. A minimal purity of 98% was confirmed, and 
appropriate cell populations were mixed in a 1:1 ratio. A total of 2 × 106 
cells were intraperitoneally injected into Rag1−/− recipient mice. 
Animals were euthanized 21 days after injection, and secondary 
lymphatic organs were analyzed for T cell numbers, subsets, and 
origin (CD45.1 versus CD45.2).
Transfer colitis and protection
Splenocytes were sorted on the basis of CD4-PE and CD45Rb-FITC 
staining for CD4+ CD45RBhi and CD4+ CD45RBlo, as described 
previously (23). A minimum purity of 98% was ensured. For the 
induction of transfer colitis, Rag1−/− received 0.5 × 106 CD45Rbhi 
cells from either L2/L2 or cKO mice by intraperitoneal injection. 
For transfer colitis protection experiments, Rag1−/− animals were 
intraperitoneally injected with 0.5 × 106 CD4+ CD45Rbhi cells from 
Ly5.1 donor mice and 0.25 × 106 CD4+ CD45Rblo T cells from either 
L2/L2 or cKO mice. In both experiments, body weight was recorded 
to monitor disease progression and estimate colitis severity. Ani-
mals were euthanized once most of the mice reached a critical 
weight loss of 20%. Cells from secondary lymphatic organs were 
isolated, stained for CD4 and CD45.1, and analyzed by flow cy-
tometry. CD4+ CD45.1− cells were considered as repopulating do-
nor T cells.
LCMV infection and virus-specific T cell cytotoxicity
Mice were intravenously injected with 2.5 × 105 plaque-forming 
units of LCMV strain WE in phosphate-buffered saline and eutha-
nized at day 6, 8, or 10, respectively. For characterization and intra-
cellular staining, T cells were isolated from spleen and mesenteric 
lymph node and stained as described above. Virus titers were ana-
lyzed in different organs using plaque assay, as described previously 
(41). For the detection of virus-specific cytotoxic T cells, EL4 thy-
moma cells were labeled with 3H-thymidine (10 Ci/ml) overnight 
and pretreated with gp33 or adn5 peptide. Effector cells were mixed 
with 2 × 104 target cells in triplicate at the indicated effector:target 
ratio for 16 hours before the 3H-thymidin content was determined 
by scintillation counting. DNA fragmentation was calculated as pre-
viously described (16).
Study approval
All animal experiments were performed in accordance with 
German animal experimentation regulations approved by the Ethics 
Review Board of the Regierungspräsidium Freiburg. The G*Power 
software was used to predetermine sample size of all animal 
experiments.
Statistics
Values reported are means ± SD. Statistical significance was deter-
mined by unpaired two-tailed Student’s t test using Prism (version 
6.0b, GraphPad). Where indicated, one-way analysis of variance 
(ANOVA) with Bonferroni’s multiple comparisons test was used. 
P values are indicated as follows: *P < 0.05, **P < 0.01, and ***P < 0.001. 
Confidence interval was set to 95%.
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